Corcept Therapeutics (CORT) Liabilities and Shareholders Equity (2016 - 2025)
Corcept Therapeutics (CORT) has disclosed Liabilities and Shareholders Equity for 14 consecutive years, with $836.7 million as the latest value for Q4 2025.
- Quarterly Liabilities and Shareholders Equity changed 0.46% to $836.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.3 billion through Dec 2025, up 10.45% year-over-year, with the annual reading at $836.7 million for FY2025, 0.46% changed from the prior year.
- Liabilities and Shareholders Equity hit $836.7 million in Q4 2025 for Corcept Therapeutics, up from $823.6 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $846.5 million in Q1 2025 to a low of $423.8 million in Q4 2021.
- Historically, Liabilities and Shareholders Equity has averaged $643.6 million across 5 years, with a median of $605.9 million in 2023.
- Biggest five-year swings in Liabilities and Shareholders Equity: fell 25.88% in 2021 and later skyrocketed 37.68% in 2022.
- Year by year, Liabilities and Shareholders Equity stood at $423.8 million in 2021, then soared by 37.68% to $583.4 million in 2022, then grew by 6.53% to $621.5 million in 2023, then skyrocketed by 35.24% to $840.6 million in 2024, then dropped by 0.46% to $836.7 million in 2025.
- Business Quant data shows Liabilities and Shareholders Equity for CORT at $836.7 million in Q4 2025, $823.6 million in Q3 2025, and $801.7 million in Q2 2025.